Single-Dose Absorption and Pharmacokinetics of WR 6026. Phase 1
Abstract
WR 6026 is a promising agent for the treatment of visceral leishmaniasis based on experiments in both an animal model and an in vitro test system. This human study was performed in order to increase our understanding of the pharmacokinetics, safety, and tolerance of a single oral 60 mg dose of WR 6026 in healthy male volunteers. Following the administration of a single dose of 60 mg of WR 6026, serial blood specimens and urine collections were obtained in order to assess the pharmacokinetics of this compound. The volunteers were monitored for subjective tolerance by daily interview and for objective toxicity with clinical laboratory tests of hematology and chemistry variables, electrocardiograms, urinalysis, and methemoglobin determinations. All of the subjects tolerated WR 6026 very well with no adverse symptoms. No subject had a significant change in hematological parameters, electrocardiograms, methemoglobin, creatine kinase or urinalysis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1988
- Accession Number
- ADA198294
Entities
People
- Brent G. Petty
- David M. Kornhauser
- Paul S. Lietman
- Theresa B. Shapiro
Organizations
- Johns Hopkins University